advanced search

RESPIRATORY

PULMONARY
DEVELOPING ROBUST ORALLY INHALED PRODUCTS TO ACHIEVE BETTER PATIENT OUTCOMES
Clair Brooks looks at some of the in-use issues and patient effects that good design of devices for orally inhaled drug products can address within the context of regulatory requirements for the demonstration of robustness.
RESPIRATORY
TRANSFORMING MENTAL HEALTHCARE: THE RISE OF INHALABLE PSYCHEDELICS?
Philippe Rogueda discusses how inhaled psychedelic therapies are emerging as a potential game-changer in mental health due to their fast onset and precise dosing, and how their potential has resulted in a growing pipeline of therapies, paving the way for a new era in mental healthcare.
THE POWER OF PULMONARY: ADVANCES IN INHALED DRUG DELIVERY EXPAND RESPIRATORY TREATMENT OPTIONS
PULMONARY
Jonathan Mulpas
Aptar Pharma
THE POWER OF PULMONARY: ADVANCES IN INHALED DRUG DELIVERY EXPAND RESPIRATORY TREATMENT OPTIONS
Jonathan Mulpas discusses how advanced inhaled drug delivery devices, such as dry powder inhalers and non-propellant liquid inhalers, can meet currently unmet needs in the inhalation space, focusing on devices that Aptar and its partners are developing to realise this potential and the expertise that Aptar can offer in this area.
BLISTERS, BONDS AND BIOLOGICS: HOW TO ACHIEVE STABILITY OF DRY POWDER BIOLOGICS
EXPERT VIEW
Dr Heather Jameson
BLISTERS, BONDS AND BIOLOGICS: HOW TO ACHIEVE STABILITY OF DRY POWDER BIOLOGICS
Heather Jameson and Dave Farrow cover the challenging formulation science required to develop a viable dry powder aerosol and examine the inhaler device requirements necessary to protect the formulation throughout its shelf life while also ensuring consistent, high-performance delivery.
SHIELDED THERAPEUTICS: COULD POLYMERIC NANOPARTICLES SAFEGUARD A NEW GENERATION OF INHALED DRUGS?
EXPERT VIEW
Kamaal de Silva
SHIELDED THERAPEUTICS: COULD POLYMERIC NANOPARTICLES SAFEGUARD A NEW GENERATION OF INHALED DRUGS?
Kamaal de Silva and Ethan Miller provide an overview of the benefits of polymeric nanoparticles in pulmonary drug delivery and their potential to overcome key challenges in respiratory medicine, while summarising the range of pulmonary delivery devices that could benefit from their use.
MANUFACTURE OF MOISTURE-SENSITIVE POWDERS FOR INHALATION
PULMONARY
Dr Alan Watts
Catalent Pharma Solutions
MANUFACTURE OF MOISTURE-SENSITIVE POWDERS FOR INHALATION
Alan Watts, Yusuf Ahmed and Gabriela Dujovny discuss manufacturing methods for inhalation powders and explain how moisture protection is an essential consideration throughout the manufacturing process.
NOSE-TO-BRAIN DELIVERY: PATIENT-CENTRIC DEVICE DEVELOPMENT AND PERFORMANCE TESTING
NASAL
Sophie Conte
Nemera
NOSE-TO-BRAIN DELIVERY: PATIENT-CENTRIC DEVICE DEVELOPMENT AND PERFORMANCE TESTING
Sophie Conte and Alain Regard, describe Nemera’s journey in nose-to-brain device development, highlighting the evaluation tools, methods and usability testing developed in-house to steer innovative device design and engineering.
MEETING THE DEMAND FOR PATIENT CENTRICITY WITH NASAL SPRAY REPOSITIONING
EXPERT VIEW
Eric Kaneps
MEETING THE DEMAND FOR PATIENT CENTRICITY WITH NASAL SPRAY REPOSITIONING
Eric Kaneps discusses key emerging drug delivery trends poised to help the pharmaceutical industry meet the growing demand for patient-centric solutions, with a particular focus on nasal drug delivery, as the nasal spray repositioning of existing drugs offers a range of benefits, including rapid onset of action, improved bioavailability and ease of administration for patients.
REALISTIC BREATHING PROFILES IN IN SILICO MODELS: A PARTNERSHIP APPROACH
PULMONARY
Dr Carolina Dantas
Pulmotree Medical
REALISTIC BREATHING PROFILES IN IN SILICO MODELS: A PARTNERSHIP APPROACH
Carolina Dantas, Ulf Krueger and Howard Burnett discuss the critical need for precision when delivering biologics to the lungs, how PULMOTREE’s Kolibri is able to achieve this using guided breathing, and how the use of realistic breathing profiles can improve outcomes and decrease risk with in vitro and in silico testing.
CONFERENCE PREVIEW: SMI.LONDON
CONFERENCE SHOWCASE
CONFERENCE PREVIEW: SMI.LONDON
Join colleagues from across the inhalation space at SMI.London 2025, the only conference dedicated to soft mist inhalers (SMIs) worldwide. The event will take place on Wednesday, June 25, 2025, at the Pullman London St Pancras, hosted by Merxin.
THE ROLE OF METAL DEEP-DRAWN PARTS IN MEDICAL DEVICES FOR DRUG DELIVERY
INDUSTRIALISATION
Dennis Gossmann
STÜKEN Medical
THE ROLE OF METAL DEEP-DRAWN PARTS IN MEDICAL DEVICES FOR DRUG DELIVERY
Dennis Gossmann discusses the benefits of using deep-drawn metal components in drug delivery devices and how STÜKEN MEDICAL, as an established expert in this field, can be an ideal partner for manufacturing and supplying these parts.
REFORMULATING pMDIS WITH NEXT-GENERATION SUSTAINABLE PROPELLANTS
SUSTAINABILITY
Ross Errington
Bespak
REFORMULATING pMDIS WITH NEXT-GENERATION SUSTAINABLE PROPELLANTS
Ross Errington and Simon Gardner, discuss sustainability and the reformulation of pMDIs with low-GWP propellants.
INNOVATIVE ACOUSTIC NEBULISER TECHNOLOGY
PULMONARY
Andrea Cusack
Nebu~Flow
INNOVATIVE ACOUSTIC NEBULISER TECHNOLOGY
Andrea Cusack, Elijah Nazarzadeh and John Pritchard share insights into the company’s innovative nebuliser platform, designed to overcome the technical restrictions of current technologies that limit the delivery of advanced medicines to the lungs. They also share an update on the development of new digital features for the Nebu-Flow product range.
INTERVIEW: PUREHALE<sup>®</sup> AND THE FUTURE OF FINE MIST DISPENSERS FOR UPPER AIRWAY TREATMENTS
INTERVIEW
Julien Storz
Aptar Pharma
INTERVIEW: PUREHALE® AND THE FUTURE OF FINE MIST DISPENSERS FOR UPPER AIRWAY TREATMENTS
Julien Storz and Giulia Mueller discuss the latest trends and treatment options available for upper airway conditions, along with the many benefits offered by Aptar Pharma’s advanced PureHale® systems to manufacturers.
TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS
EXPERT VIEW
Mark Parry
TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS
Mark Parry, John McLaughlin and Tino Otte discuss the necessary studies required to understand the nitrosamine formation and leachables profiles of new pMDI propellants with lower global warming potentials as part of the pharmaceutical industry’s drive to reduce its emissions and environmental impact.
BREEASE – DESIGNED TO ALLEVIATE BREATHING FOR INFANTS AND TODDLERS
RESPIRATORY
Dr Marie-Christine Klein
URSATEC
BREEASE – DESIGNED TO ALLEVIATE BREATHING FOR INFANTS AND TODDLERS
Marie-Christine Klein, Christian Weyler and Dr Fredrik Bokvist, discuss the effects of air pollution on health – and how the Breease pacifier could help babies and young children.
ENVIRONMENTAL BENEFITS OF BEDSIDE IONIC NITRIC OXIDE GENERATION
EXPERT VIEW
David Webster
ENVIRONMENTAL BENEFITS OF BEDSIDE IONIC NITRIC OXIDE GENERATION
David Webster and Mark Rimkus consider the environmental impact of traditional high-pressure storage systems for nitric oxide and highlight the benefits associated with bedside ionic generation.
IMPROVING AEROSOL DELIVERY: NANOSUSPENSION & MESH TECHNOLOGY
PULMONARY
Edgar Hernan Cuevas Brun
HCmed Innovations
IMPROVING AEROSOL DELIVERY: NANOSUSPENSION & MESH TECHNOLOGY
Edgar Hernan Cuevas Brun and Yuchi Chen, discuss how the combination of Formosa’s APNT formulation technology and HCmed’s AdheResp smart breath-actuated mesh nebuliser can work together to offer significant benefits to the aerosolisation of difficult solution-based formulations for inhalation.
STRATEGIES FOR SELECTING THE RIGHT CDMO FOR NASAL DRUG DELIVERY
NASAL
Mark Ignaczak
Catalent Pharma Solutions
STRATEGIES FOR SELECTING THE RIGHT CDMO FOR NASAL DRUG DELIVERY
Mark Ignaczak explores the current nasal drug delivery landscape and outlines key considerations for choosing the right CDMO to ensure the success of nasal drug projects.
THE pMDI DILEMMA: MANAGING PATIENT NEEDS, HEALTH AND THE PLANET
SUSTAINABILITY
Nick Smalley
Kindeva Drug Delivery
THE pMDI DILEMMA: MANAGING PATIENT NEEDS, HEALTH AND THE PLANET
Nick Smalley discusses the balancing act involved in meeting patients’ therapeutic needs while protecting the planet when it comes to pMDI development.
Pharmapack Preview: An INTERVIEW with ALASTAIR WILLOUGHBY
INTERVIEW
Alastair Willoughby
Team Consulting
Pharmapack Preview: An INTERVIEW with ALASTAIR WILLOUGHBY
CPHI Milan this year included a key discussion led by Team Consulting’s Alastair Willoughby on “Understanding the Problem of Decarbonisation in Drug Delivery”; one of the industry’s critical challenges. These themes will be discussed in greater depth at Pharmapack Europe in Paris in January.
NOLATO’S VIRTUAL FACTORY
INDUSTRIALISATION
Patrik Ingvarsson
Nolato Group
NOLATO’S VIRTUAL FACTORY
Patrik Ingvarsson, showcases the Nolato's virtual factory, highlighting the advantages of virtual tools for product development in the medical device industry.
Interview with Bespak’s Louise Righton & Benedicta Bakpa
INTERVIEW
Louise Righton
Bespak
Interview with Bespak’s Louise Righton & Benedicta Bakpa
An increasing global incidence of respiratory diseases, such as asthma and COPD, is driving demand for therapies. Simultaneously, greenhouse gas emissions continue to rise, so the pharma industry must consider how to produce much-needed nasally delivered and orally inhaled medicines whilst minimising environmental impact. Louise Righton and Benedicta Bakpa discuss the many different aspects involved in driving sustainability in inhaled drug delivery – and the next steps.
CREATING VALUE – SUSTAINABLE APPROACHES FOR THE MEDICAL DEVICE INDUSTRY
SUSTAINABILITY
David Pircher
Baumann Medical
CREATING VALUE – SUSTAINABLE APPROACHES FOR THE MEDICAL DEVICE INDUSTRY
David Pircher provides insights from a sustainability journey, showcasing what suppliers can contribute and how innovation and partnership support a common vision. The article outlines where the industry stands and why sustainability is a top priority, with concrete examples.
FUTURE-PROOFING YOUR DRUG DELIVERY DEVICE: CONSIDERATIONS FOR EFFECTIVE DESIGN
INDUSTRIALISATION
Lorenzo Vaccarella
Paragon Medical
FUTURE-PROOFING YOUR DRUG DELIVERY DEVICE: CONSIDERATIONS FOR EFFECTIVE DESIGN
Lorenzo Vaccarella highlights six critical areas to consider early in the drug delivery device development journey. He discusses how strategically investing time during the early stages of the design cycle and throughout development can ultimately save both time and cost down the road when the product is being manufactured and deployed into the market.
OPTIMISING INHALATION ADHERENCE AND TECHNIQUE: THE POWER OF DIGITAL TECHNOLOGY
CONNECTIVITY
Dr Carola Fuchs
PARI
OPTIMISING INHALATION ADHERENCE AND TECHNIQUE: THE POWER OF DIGITAL TECHNOLOGY
Carola Fuchs and Rupa Ram discuss the development of PARI’s new eFlow Integrated Nebuliser and the PARI Breath Guide app, and how integrating these into the PARI Connect Platform will stimulate increased adherence to inhaled therapy and, therefore, improved therapeutic outcomes. 
Top